Medsenic Announces Positive Results of its Phase II clinical trial for the treatment clinical trial for the treatment of chronic graft-versus-host disease (cGvHD).
Strasbourg, France, March 29, 2021 - Medsenic, a clinical-stage biopharmaceutical company specialising in the discovery and development of novel indications and formulations of arsenic salts for the treatment of severe autoimmune diseases, today announced positive results from its Phase II GMED16-001 clinical study with its lead product, Arscimed®, an IV formulation of arsenic trioxide, in patients with chronic graft-versus-host disease GvHD.
Click on this link to access the full press release.